ASCO Annual Meeting

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a manageable safety profile.

In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual Meeting.

Higher pretreatment HER2 amplicon mRNA and HER2 protein levels predicted improved time to next treatment with T-DXd in metastatic breast cancer. Conversely, higher TOPO1 protein correlated with worse outcomes.

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and progression-free survival in recent clinical trials.

Adding cobolimab to dostarlimab as neoadjuvant treatment for high-risk resectable melanoma improved major pathological response rates and was tolerable.

Undetectable ctDNA at cycle 6 strongly predicts reduced progression/death risk in locally advanced cervical cancer patients treated with durvalumab/CRT or CRT alone.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

A single cilta-cel infusion led to 33% of heavily pretreated relapsed/refractory multiple myeloma patients remaining progression-free at 5+ years.

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ovarian cancer, warranting further study.

Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response rates in intermediate-to-high-risk prostate cancer.

Alicia Morgans, MD, MPH, discusses the phase 3 ARASTEP trial evaluating darolutamide in patients at high risk of biochemical recurrence of prostate cancer.

Ziftomenib shows promising results in treating relapsed/refractory NPM1-mutant AML, achieving significant remission rates and a favorable safety profile.

Neoadjuvant nivolumab plus chemotherapy significantly improves overall survival in resectable non-small cell lung cancer, marking a treatment breakthrough.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

The ongoing ARASTEP trial evaluates darolutamide plus ADT vs placebo for high-risk prostate cancer biochemical recurrence with PSMA PET-CT-positive lesions, aiming to improve rPFS.

Lifileucel therapy shows promising long-term survival and response rates in advanced melanoma patients, offering hope for those with limited treatment options.

Olaparib and radium-223 bested radium-223 alone in radiographic progression-free survival in men with castration-resistant prostate cancer.

Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical cancer.

Meghan Mooradian, MD, discusses findings and implications of the phase 2 NEO-MEL-T study.

Darolutamide significantly delayed pain progression and improved overall well-being in patients with metastatic hormone-sensitive prostate cancer.

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in high-risk locally advanced cervical cancer, establishing a new standard of care.

The FIRST/ENGOT-OV44 trial found dostarlimab plus platinum-chemo and niraparib maintenance modestly improved PFS (20.6 vs 19.2 months) in advanced ovarian cancer, with expected safety.

DeLLphi-304 trial results showed tarlatamab significantly improved PFS and OS over chemotherapy in second-line SCLC, establishing it as a new standard.

A prophylactic dermatologic regimen significantly reduced skin side effects and improved quality of life for NSCLC patients on amivantamab/lazertinib.

Benmelstobart alone or with anlotinib improved progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

Atezolizumab plus cabozantinib or cabozantinib alone showed efficacy and manageable safety in second-line renal cell carcinoma.

The ALNEO trial's final analysis shows neoadjuvant alectinib is effective and well tolerated in resectable stage III ALK-positive NSCLC, achieving 42% MPR and 67% ORR, suggesting a feasible perioperative option.